LANXESS worldwide

Corporate Website en | de


  • Australia en

  • China cn | en

  • India en

  • Indonesia en

  • Japan jp

  • Korea kr

  • Malaysia en

  • Pakistan en

  • Philippines en

  • Singapore en

  • Thailand en

  • Vietnam en


  • Austria en

  • Belgium nl

  • Czech en

  • France fr

  • Hungary en

  • Italy en

  • Netherlands en

  • Poland en

  • Russia en

  • Serbia en

  • Slovakia en

  • Spain en

  • Turkey en

  • United Arab Emirates en

  • United Kingdom en



LANXESS Canada Contacts

Contact our Sites in Canada

Elmira, Ontario

West Hill, Ontario

Corporate Communications
Business & General Press

Michael Mackin
111 RIDC Park West Drive
Pittsburgh, PA 15275 - 1112
Phone: +1 412 809 4726
Mobile: +1 412-290-5491

Trade & Technical Press

Leanne Trevelline
111 RIDC Park West Drive
Pittsburgh, PA 15275 - 1112

Phone: +1 412 809 1515

Global Press Releases


Saltigo at CPhI Worldwide in Milan, Italy, November 9 to 11, 2021, stand 5D36

Reliable partner for the pharmaceutical industry and fine chemistry

Leverkusen, November 3, 2021 – With its comprehensive service range based around the exclusive synthesis of chemical agents and intermediates, Saltigo GmbH, a globally active subsidiary of the specialty chemicals company LANXESS, will be at CPhI Worldwide 2021, which will take place in Milan, Italy, from November 9 to 11. In addition to the agrochemical industry, customers of the Leverkusen-based specialist in exclusive synthesis include pharmaceutical companies and buyers of fine chemicals.

Focus on quality and delivery reliability

In relation to precursors and intermediates for the pharmaceutical industry in particular, where consistently high quality and high delivery reliability are key, Dr. Christoph Schaffrath, Head of Marketing and Sales at Saltigo, also sees good market opportunities for the future. “For a long time now, we have had an ongoing working relationship with numerous pharmaceutical companies who value our reliability and expertise,” he explains. One example of such a precursor is 1,2,4-(1H)-triazole, which is not produced exclusively and is used to make an antiviral active ingredient for oral application. 1,1’-carbonyldiimidazole is also widely used in coupling reactions in the process of making pharmaceutical active ingredients.

In the area of exclusive synthesis, it is the core competencies of Saltigo in particular, including hydrogenation in a pressurized environment and at high temperatures or catalyzed coupling reactions that attract a high level of interest from customers. Services such as process development, pilot testing, analytics and supporting customers through the registration of new substances complete the portfolio.

“Customer, technology and project need to be a good fit”

Synthesis steps under clean room conditions, at low temperatures, with complexreagents or in an inert gas atmosphere, as they are frequently encountered in theprocess for making active ingredients, also play an important role in other areas.This enables synergies to be exploited in respect of expertise as well as thetechnologies involved.

For example, a current field of activity at Saltigo in the fine chemistry sector iselectrolytes for lithium-ion batteries. “Thanks to our broad-based technologicalexpertise, we are extremely well positioned there too. Generally, the industry isless important than the customer, technology and project being a good fit,” saysDr. Michael Zobel, Chief Executive Officer of Saltigo GmbH, with conviction.Organic redox flow batteries could open up further prospects in the future assoon as the technology is market-ready. Redox-active electrolyte systems arerequired for this. “In this context, various substances are currently being testedfor their suitability, and we can well imagine supporting appropriatemanufacturers from scaling up the laboratory regulations up to production for themarket launch and beyond,” explains Schaffrath.

Detailed information about the comprehensive range of services offered bySaltigo in the area of exclusive synthesis can be found online at

Forward-Looking Statements
This company release contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors, nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.

Information for editors:
All LANXESS news releases and their accompanying photos can be found at Recent photos of the Board of Management and other LANXESS image material are available at 

You can find further information concerning LANXESS chemistry in our digital magazine “Inside LANXESS” at

Follow us on Twitter, Facebook, LinkedIn and YouTube:

LANXESS is a leading specialty chemicals company with sales of EUR 6.1 billion in 2020. The company currently has about 14,900 employees in 33 countries. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives, specialty chemicals and plastics. LANXESS is listed in the leading sustainability indices Dow Jones Sustainability Index (DJSI World and Europe) and FTSE4Good.